» Articles » PMID: 21790895

Cyclin D2 is Overexpressed in Proliferation Centers of Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma

Overview
Journal Cancer Sci
Specialty Oncology
Date 2011 Jul 28
PMID 21790895
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The D cyclins are important cell cycle regulatory proteins involved in the pathogenesis of some lymphomas. Cyclin D1 overexpression is a hallmark of mantle cell lymphoma, whereas cyclins D2 and D3 have not been shown to be closely associated with any particular subtype of lymphoma. In the present study, we found that cyclin D2 was specifically overexpressed in the proliferation centers (PC) of all cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) examined (19/19). To examine the molecular mechanisms underlying this overexpression, we immunohistochemically examined the expression of nuclear factor (NF)-κB, p15, p16, p18, and p27 in the PC of six patients. Five cases showed upregulation of NF-κB expression, which is known to directly induce cyclin D2 by binding to the promoter region of CCND2. All six PC examined demonstrated downregulation of p27 expression. In contrast, upregulation of p15 expression was detected in five of six PC examined. This discrepancy suggests that unknown cell cycle regulatory mechanisms involving NF-κB-related pathways are also involved, because NF-κB upregulates cyclin D2 not only directly, but also indirectly through c-Myc, which is believed to downregulate both p27 and p15. In conclusion, cyclin D2 is overexpressed in the PC of CLL/SLL and this overexpression is due, in part, to the upregulation of NF-κB-related pathways.

Citing Articles

The Role of the Microenvironment and Cell Adhesion Molecules in Chronic Lymphocytic Leukemia.

Cerreto M, Foa R, Natoni A Cancers (Basel). 2023; 15(21).

PMID: 37958334 PMC: 10647257. DOI: 10.3390/cancers15215160.


Robust CRISPR-Cas9 Genetic Editing of Primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells.

Mateos-Jaimez J, Mangolini M, Vidal A, Kulis M, Colomer D, Campo E Hemasphere. 2023; 7(6):e909.

PMID: 37304935 PMC: 10249715. DOI: 10.1097/HS9.0000000000000909.


Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma.

Alvarez-Benayas J, Trasanidis N, Katsarou A, Ponnusamy K, Chaidos A, May P Nat Commun. 2021; 12(1):5450.

PMID: 34521827 PMC: 8440555. DOI: 10.1038/s41467-021-25704-2.


Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?.

Haselager M, Kater A, Eldering E Front Oncol. 2020; 10:592205.

PMID: 33134182 PMC: 7578574. DOI: 10.3389/fonc.2020.592205.


CLL intraclonal fractions exhibit established and recently acquired patterns of DNA methylation.

Bartholdy B, Wang X, Yan X, Pascual M, Fan M, Barrientos J Blood Adv. 2020; 4(5):893-905.

PMID: 32150608 PMC: 7065474. DOI: 10.1182/bloodadvances.2019000817.


References
1.
Chiorazzi N, Rai K, Ferrarini M . Chronic lymphocytic leukemia. N Engl J Med. 2005; 352(8):804-15. DOI: 10.1056/NEJMra041720. View

2.
Solvason N, Wu W, Parry D, Mahony D, Lam E, Glassford J . Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development. Int Immunol. 2000; 12(5):631-8. DOI: 10.1093/intimm/12.5.631. View

3.
Kosmaczewska A, Ciszak L, Szteblich A, Laba A, Wojtowicz M, Wolowiec D . Is cyclin D2 a marker of B-cLL cell activation?. Oncol Res. 2010; 18(2-3):127-31. DOI: 10.3727/096504009789954663. View

4.
Yatabe Y, Suzuki R, Tobinai K, Matsuno Y, Ichinohasama R, Okamoto M . Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood. 2000; 95(7):2253-61. View

5.
Hewamana S, Lin T, Rowntree C, Karunanithi K, Pratt G, Hills R . Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. J Clin Oncol. 2009; 27(5):763-9. DOI: 10.1200/JCO.2008.19.1114. View